Ugur Sahin, BioNTech CEO (Andreas Arnold/dpa via AP Images)
December 22, 2020 07:33 AM ESTUpdated 10:02 AM
Coronavirus

Covid-19 roundup: Pfiz­er/BioN­Tech/Mod­er­na test vac­cines against new UK vari­ant; Ocu­gen strikes deal for US rights to PhI­II vac­cine

Nicole DeFeudis

Editor

Both Pfiz­er/BioN­Tech and Mod­er­na have said their can­di­dates should pro­tect against a new vari­ant of coro­n­avirus that has been de­tect­ed in the UK, and are …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times